| Disease | myeloid disorders: MDS in more than half cases, ANLL in 1/4 of cases, chronic myeloproliferative syndrome ('atypical CML'); exceptionally: lymphoproliferations; therefore, only trisomy 14 solely in myeloid malignanies is herein described |
| Phenotype / cell stem origin | MDS: RA, RAEBħT mainly; ANLL: M1, M2, M4; atypical CML: with dysplastic features |
| Epidemiology | median age 60-65 yrs (range: 4-89 yrs); sex ratio: 4M/3F |
| Clinics | no history of carcinogen exposure of note; blood data: platelets count: 130 X 109/l; monocytosis in half cases |
| Cytology | all FAB subtypes of MDS can be found; atypical CML cases present with dysplastic features; non-lobulated megakaryocytes are often found |
| Prognosis | survival < 2yrs in most cases; +14 do not seem to bear a distinct prognosis |
| Trisomy 14 is a non-random karyotypic abnormality associated with myeloid malignancies. |
| Toze CL, Barnett MJ, Naiman SC, Horsman DE |
| British journal of haematology. 1997 ; 98 (1) : 177-185. |
| PMID 9233582 |
| |
| Four additional cases of trisomy 14 as the sole anomaly in various haematological malignancies. |
| Brizard A, Guilhot F, Babin P, Burucoa C, Tanzer J, Huret JL |
| Leukemia research. 1992 ; 16 (5) : 537-540. |
| PMID 1625480 |
| |